Inve US ▾
PVPVLA

Palvella Therapeutics (PVLA) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

Palvella Therapeutics Q2 FY26 — NDA Submission Progress and Pipeline Expansion

Palvella Therapeutics made significant strides in Q2 FY26, advancing its lead asset, QTORIN rapamycin, towards FDA approval for microcystic lymphatic malformations (MLM) with the first NDA module submitted. The company is also expanding its pipeline across multiple rare skin diseases, leveraging its QTORIN platform and a strong cash position to invest in pre-launch activities and clinical development. Management remains focused on bringing first-in-disease therapies to patients with high unmet needs.

Highlights

5

  • Completed submission of the first module of the NDA for QTORIN rapamycin in microcystic lymphatic malformations (MLM), remaining on track for full submission in H2 2026 and potential FDA approval in H1 2027.

  • Achieved compelling safety and efficacy results from the Phase III SELVA study, with 95% of patients demonstrating improvement on the primary endpoint at week 24.

  • Strengthened balance sheet with approximately $251 million in cash at quarter-end, providing capital through potential FDA approval and commercial launch.

  • Expanded planned sales force at launch to approximately 40 sales reps, at the upper end of prior guidance, to strengthen field coverage and physician education.

  • Initiated Phase II LOTU study for QTORIN rapamycin in clinically significant angiokeratomas earlier than expected, with data anticipated in H2 2027.

Concerns

1

  • Breakthrough Therapy Designation for cutaneous venous malformations (cVM) was not granted based on initial 12-week data, though a resubmission is planned with 24-week data.

Guidance & targets

CategoryTargetConfidence
QTORIN rapamycin NDA submission (MLM)
Complete NDA submission
high materiality
High
QTORIN rapamycin FDA approval (MLM)
Potential FDA approval
high materiality
High
QTORIN rapamycin FDA approval (cVM)
Potential FDA approval
medium materiality
Medium
QTORIN rapamycin FDA approval (angiokeratomas)
Potential FDA approval
medium materiality
Medium
Fourth QTORIN rapamycin indication
Announce fourth indication
low materiality
High
Cash expenses
$85M-$95M
medium materiality
High

Risks & headwinds

Breakthrough Therapy Designation for cVM not granted

Initial request based on 12-week data was not granted

Mitigation:Plan to resubmit with complete 24-week efficacy data set and final Phase II qualitative report after upcoming FDA interaction and Phase III initiation.

What to watch in Q3 FY26

QTORIN rapamycin NDA submission

H2 FY26
Current First module submitted
Target Full NDA submission completed

Why it matters

Completion of the NDA submission is a critical step towards potential FDA approval and commercialization of the lead asset.

I am pleased to report today that, #1, we remain on track to complete our NDA submission in the second half of this year.

Find out whether PVLA delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you elaborate on efforts to identify MLM patients and confirm if recent findings align with the initial estimate of ~30,000 diagnosed patients?

Recent findings confirm the estimate of greater than 30,000 diagnosed MLM patients in the U.S., with an estimated annual incidence of 1,500+ new diagnoses. Patient identification focuses on high-volume vascular anomaly centers and physicians, supported by strong presence at medical congresses.

“I can confirm that our recent findings are in line with previous estimates. Last year, we published a claims analysis at a medical congress that indicated somewhere between 45,000 and 95,000 diagnosed MLM patients in the U.S. Importantly, in that analysis that's published, there was also an estimated annual incidence of 1,500 or more newly diagnosed patients that will come into that pool.”

asked by Alexa Deemer · answered by Wesley Kaupinen

2 min read 6 chapters

Detailed narrative

NDA Progress for Microcystic Lymphatic Malformations (MLM)

Palvella achieved significant milestones for QTORIN rapamycin in MLM, including a pre-NDA meeting with the FDA, granted rolling review status, and the submission of the first module of its NDA. The company remains on track to complete the full NDA submission in the second half of 2026 and anticipates potential FDA approval in the first half of 2027. The application is supported by Breakthrough Therapy, Fast Track, and Orphan Drug Designations, leveraging the 505(b)(2) regulatory pathway.

Pipeline-in-a-Product Strategy and Market Opportunity

QTORIN rapamycin is being developed as a pipeline-in-a-product, targeting multiple rare diseases driven by mTOR signaling. The strategy aims to expand the addressable U.S. patient population from over 30,000 in MLM to over 300,000 across multiple indications, including cutaneous venous malformations (cVM) and clinically significant angiokeratomas. Palvella focuses on diseases with no FDA-approved treatments and multi-billion dollar total addressable markets, based on data-driven epidemiological work.

Launch Readiness and Commercial Investments

Palvella is actively preparing for the potential U.S. launch of QTORIN rapamycin, having assembled a leadership team with deep rare disease and dermatology experience. Key pre-launch activities include engaging target clinics, building patient services infrastructure, and conducting payer research. The company has increased its planned sales force to approximately 40 reps and is making additional investments in medical affairs and marketing to ensure a successful launch and efficient patient access.

Clinical Data and Therapeutic Profile of QTORIN Rapamycin

The Phase III SELVA study for MLM demonstrated highly compelling results, with 95% of patients showing improvement on the primary endpoint and a favorable safety profile. New analysis in children aged 6-11 showed a rapid, large-magnitude treatment effect, with every child rated as much or very much improved. The innovative trial design, including an 8-week untreated run-in period, objectively confirmed that observed improvements resulted from QTORIN rapamycin treatment.

Advancement of Cutaneous Venous Malformations (cVM) Program

The Phase II TOIVA study for cVM showed 73% of patients improved on the cVM-IGA, exceeding the predefined success threshold. Palvella plans to initiate a Phase III study in Q4 2026, following an End of Phase II meeting with the FDA to finalize the pivotal study design. Despite not receiving Breakthrough Therapy Designation initially, the company plans a resubmission with complete 24-week efficacy data and qualitative patient reports.

Progress in Angiokeratomas and DSAP Programs

The Phase II LOTU study for clinically significant angiokeratomas, a natural extension of the QTORIN rapamycin strategy, has dosed its first patients ahead of schedule, with data expected in H2 2027. This program is expected to follow a supplemental NDA pathway. For disseminated superficial actinic porokeratosis (DSAP), the QTORIN pitavastatin program remains on track for Phase II initiation in Q4 2026, targeting a chronic, precancerous skin disease with high unmet need.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.